CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces...

✨ #CARsgen annonce des données positives pour les produits #CAR_T 🧬 #Allogéniques #CT0596 ciblant #BCMA pour le #MyélomeMultiple 🩸 R/R, et pour #CT1190B, un produit candidat CAR-T allogénique ciblant #CD19/#CD20 pour le #Lymphome 🩸 non hodgkinien #LNH R/R.
www.prnewswire.com/news-release...

CARsgen Therapeutics Announces Promising Results for CAR-T Therapies CT0596 and CT1190B CARsgen Therapeutics reveals encouraging clinical outcomes for its allogeneic CAR-T products CT0596 and CT1190B, targeting multiple myeloma and non-Hodgkin lymphoma, respectively.

CARsgen Therapeutics Announces Promising Results for CAR-T Therapies CT0596 and CT1190B #China #Shanghai #CARsgen_Therapeutics #CT0596 #CT1190B